- Home
- CYH vs MBX Comparison
CYH vs MBX Comparison
Compare CYH & MBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYH
- MBX
- Stock Information
- Founded
- CYH 1985
- MBX 36
- Country
- CYH United States
- MBX United States
- Employees
- CYH N/A
- MBX N/A
- Industry
- CYH Hospital/Nursing Management
- MBX
- Sector
- CYH Health Care
- MBX
- Exchange
- CYH Nasdaq
- MBX NYSE
- Market Cap
- CYH 623.8M
- MBX 644.6M
- IPO Year
- CYH 1991
- MBX 2024
- Fundamental
- Price
- CYH $3.29
- MBX $10.23
- Analyst Decision
- CYH Hold
- MBX Strong Buy
- Analyst Count
- CYH 6
- MBX 4
- Target Price
- CYH $4.40
- MBX $37.25
- AVG Volume (30 Days)
- CYH 2.0M
- MBX 360.9K
- Earning Date
- CYH 02-18-2025
- MBX 02-16-2025
- Dividend Yield
- CYH N/A
- MBX N/A
- EPS Growth
- CYH N/A
- MBX N/A
- EPS
- CYH N/A
- MBX N/A
- Revenue
- CYH $12,551,000,000.00
- MBX N/A
- Revenue This Year
- CYH $1.16
- MBX N/A
- Revenue Next Year
- CYH $1.18
- MBX N/A
- P/E Ratio
- CYH N/A
- MBX N/A
- Revenue Growth
- CYH 0.81
- MBX N/A
- 52 Week Low
- CYH $2.51
- MBX $9.42
- 52 Week High
- CYH $6.29
- MBX $27.50
- Technical
- Relative Strength Index (RSI)
- CYH 54.72
- MBX N/A
- Support Level
- CYH $2.88
- MBX N/A
- Resistance Level
- CYH $3.04
- MBX N/A
- Average True Range (ATR)
- CYH 0.14
- MBX 0.00
- MACD
- CYH 0.05
- MBX 0.00
- Stochastic Oscillator
- CYH 86.27
- MBX 0.00
About CYH Community Health Systems Inc.
Community Health Systems Inc is a publicly owned hospital operator in the United States. The company also owns four home health agencies and provides management and consulting services to independent hospitals. The firm derives revenue through a broad range of general and specialized hospital healthcare services and outpatient services.
About MBX MBX BIOSCIENCES INC
MBX Biosciences Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.